Inappropriate prescribing in patients accessing specialist palliative day care services

[1]  H. Holmes,et al.  Commonly Prescribed Medications in a Population of Hospice Patients , 2014, The American journal of hospice & palliative care.

[2]  A. Husband,et al.  Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? , 2013, International Journal of Clinical Pharmacy.

[3]  J. Steiner,et al.  Statin prescribing patterns in a cohort of cancer patients with poor prognosis. , 2013, Journal of palliative medicine.

[4]  F. Haaijer-Ruskamp,et al.  Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study , 2012, BMC Family Practice.

[5]  S. Pearson,et al.  Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage , 2012, BMJ Open.

[6]  H. Holmes,et al.  Tools to reduce polypharmacy. , 2012, Clinics in geriatric medicine.

[7]  J. Hugtenburg,et al.  Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Rachel P. Riechelmann,et al.  Use of unnecessary medications by patients with advanced cancer: cross-sectional survey , 2011, Supportive Care in Cancer.

[9]  O. Sibony,et al.  Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review , 2011, PloS one.

[10]  V. Girre,et al.  Potential drug interactions in elderly cancer patients. , 2011, Critical reviews in oncology/hematology.

[11]  Judith E. Fisher,et al.  Preventive medication use among persons with limited life expectancy , 2011, Progress in palliative care.

[12]  P. Hall,et al.  Non-cancer medications for patients with incurable cancer: time to stop and think? , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[13]  S. Bannister,et al.  A Qualitative Study , 2009 .

[14]  R. Riechelmann,et al.  Futile medication use in terminally ill cancer patients , 2009, Supportive Care in Cancer.

[15]  E. Steiness.  Diuretics, digitalis and arrhythmias. , 2009, Acta medica Scandinavica. Supplementum.

[16]  Lisa Wang,et al.  Potential drug interactions in cancer patients receiving supportive care exclusively. , 2008, Journal of pain and symptom management.

[17]  P. Gallagher,et al.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. , 2008, International journal of clinical pharmacology and therapeutics.

[18]  S. Oudard,et al.  Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management , 2007, Cancer.

[19]  Chia-Chien Hsu,et al.  The Delphi Technique: Making Sense of Consensus , 2007 .

[20]  Lisa Wang,et al.  Potential drug interactions and duplicate prescriptions among cancer patients. , 2007, Journal of the National Cancer Institute.

[21]  E. Erdmann,et al.  Multimedikation, Compliance und Zusatzmedikation bei Patienten mit kardiovaskulären Erkrankungen , 2007 .

[22]  T. Tanvetyanon,et al.  Physician Practice in the Discontinuation of Statins among Patients with Advanced Lung Cancer , 2006, Journal of palliative care.

[23]  A. Abernethy,et al.  Frameworks for approaching prescribing at the end of life. , 2006, Archives of internal medicine.

[24]  G. Alexander,et al.  Reconsidering medication appropriateness for patients late in life. , 2006, Archives of internal medicine.

[25]  M. Beers,et al.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. , 2003, Archives of internal medicine.

[26]  Jean Potter,et al.  Symptoms in 400 patients referred to palliative care services: prevalence and patterns , 2003, Palliative medicine.

[27]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[28]  D. Graham,et al.  Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. , 2002, Archives of internal medicine.

[29]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[30]  W. Koo,et al.  Polypharmacy in palliative care: can it be reduced? , 2002, Singapore medical journal.

[31]  I. Andrew,et al.  Futile and inappropriate prescribing: an assessment of the issue in a series of patients admitted to a specialist palliative care unit , 2001 .

[32]  H. Morris,et al.  Calcium and osteoporosis. , 1997, Annales chirurgiae et gynaecologiae.

[33]  C. Donangelo,et al.  Calcium and osteoporosis. , 1997, Archivos latinoamericanos de nutricion.

[34]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[35]  H. Cohen,et al.  A method for assessing drug therapy appropriateness. , 1992, Journal of clinical epidemiology.

[36]  E. Erdmann,et al.  [Polypharmacy, compliance and non-prescription medication in patients with cardiovascular disease in Germany]. , 2007, Deutsche medizinische Wochenschrift.

[37]  西尾 信一郎.  Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension , 2005 .

[38]  A. Callahan.  Vascular pleiotropy of statins: Clinical evidence and biochemical mechanisms , 2003, Current atherosclerosis reports.

[39]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .